For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that ...

Researchers report that acetazolamide prevented adverse brain changes caused by cocaine withdrawal in mice, suggesting the approved drug could be repurposed to target relapse-related pathways.

For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that 1 ...

Rituximab may be a safe and effective option for frequently relapsing or steroid-dependent adult-onset nephrotic syndrome, ...

Please provide your email address to receive an email when new articles are posted on . Clozapine and second-generation long-acting formulations of certain antipsychotics decreased risk for ...

NEW YORK (Reuters Health) - A treatment program incorporating mindfulness meditation is better over the long term than traditional approaches at preventing relapses of drug and alcohol abuse, ...

Medical University of South Carolina scientists report in Neuron that they have uncovered a way to restore an opioid-weakened brain pathway in a preclinical model. With funding from the National ...

Researchers find that a common glaucoma drug, acetazolamide, can reverse brain changes and prevent relapse in opioid use disorder.

Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: Many patients, including those whose cancer goes into ...

The authors reviewed the literature to identify high-quality studies (observational and controlled) of ANCA-associated vasculitis that included a predetermined target dose of steroids at the end of ...

Recovery from addiction is a challenging journey, filled with both triumphs and setbacks. For individuals seeking long-term sobriety, relapse can be a disheartening reality. However, recent findings ...

A 2015 study comparing schizophrenia patients who received oral or injectable antipsychotic medications found no difference in relapse rates between the groups. Now, a follow-up study published August ...